1
|
Kang HN, Thorpe R, Knezevic I, Casas Levano M, Chilufya MB, Chirachanakul P, Chua HM, Dalili D, Foo F, Gao K, Habahbeh S, Hamel H, Kim GH, Perez Rodriguez V, Putri DE, Rodgers J, Savkina M, Semeniuk O, Srivastava S, Tavares Neto J, Wadhwa M, Yamaguchi T. Regulatory challenges with biosimilars: an update from 20 countries. Ann N Y Acad Sci 2020; 1491:42-59. [PMID: 33222245 PMCID: PMC8247359 DOI: 10.1111/nyas.14522] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 09/29/2020] [Accepted: 10/13/2020] [Indexed: 11/29/2022]
Abstract
The World Health Organization (WHO) issued guidelines for the regulatory evaluation of biosimilars in 2009 and has provided considerable effort toward helping member states implement the evaluation principles in the guidelines into their regulatory practices. Despite this effort, a recent WHO survey (conducted in 2019–2020) has revealed four main remaining challenges: unavailable/insufficient reference products in the country; lack of resources; problems with the quality of some biosimilars (and even more with noninnovator products); and difficulties with the practice of interchangeability and naming of biosimilars. The following have been identified as opportunities/solutions for regulatory authorities to deal with the existing challenges: (1) exchange of information on products with other regulatory authorities and accepting foreign licensed and sourced reference products, hence avoiding conducting unnecessary (duplicate) bridging studies; (2) use of a “reliance” concept and/or joint review for the assessment and approval of biosimilars; (3) review and reassessment of the products already approved before the establishment of a regulatory framework for biosimilar approval; and (4) setting appropriate regulatory oversight for good pharmacovigilance, which is essential for the identification of problems with products and establishing the safety and efficacy of interchangeability of biosimilars.
Collapse
Affiliation(s)
- Hye-Na Kang
- Department of Health Product Policy and Standards, World Health Organization, Geneva, Switzerland
| | | | - Ivana Knezevic
- Department of Health Product Policy and Standards, World Health Organization, Geneva, Switzerland
| | - Mary Casas Levano
- General Directorate of Medicines Supplies and Drugs (DIGEMID), San Miguel, Peru
| | | | | | - Hui Ming Chua
- National Pharmaceutical Regulatory Agency, Selangor, Malaysia
| | - Dina Dalili
- Iran Food and Drug Administration, Tehran, Iran
| | | | - Kai Gao
- Shanghai University, Shanghai, People's Republic of China
| | | | | | - Gi Hyun Kim
- Ministry of Food and Drug Safety, Osong-eup, Republic of Korea
| | - Violeta Perez Rodriguez
- Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED), La Habana, Cuba
| | - Desi Eka Putri
- The Indonesian Food and Drug Authority, Jakarta, Indonesia
| | | | - Maria Savkina
- The Federal State Budgetary Institution "Scientific Centre for Expert Evaluation of Medicinal Products" of the Ministry of Health, Moscow, Russian Federation
| | | | - Shraddha Srivastava
- Central Drug Standards Control Organization (CDSCO), Ministry of Health & Family Welfare, New Delhi, India
| | | | - Meenu Wadhwa
- National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, United Kingdom
| | | |
Collapse
|
2
|
Wadhwa M, Kang HN, Jivapaisarnpong T, Andalucia LR, Blades CDRZ, Casas Levano M, Chang W, Chew JY, Chilufya MB, Chirachanakul P, Cho HG, Cho YO, Choi KM, Chong S, Chua HM, Farahani AV, Gencoglu M, Ghobrial MRW, Guha P, Gutierrez Lugo MT, Ha SB, Habahbeh S, Hamel H, Hong Y, Iarutkin A, Jang H, Jayachandran R, Jivapaisarnpong T, Kang HN, Kim DY, Kim GH, Kim Y, Kwon HS, Larsen J, Lee AH, Lee J, Medvedeva K, Munkombwe Z, Oh I, Park J, Park J, Putri DE, Rodgers J, Ryu S, Savkina M, Schreitmueller T, Semeniuk O, Seo M, Shin YI, Shin J, Srivastava S, Song H, Song S, Tavares Neto J, Wadhwa M, Yamaguchi T, Youn HJD, Yun M. WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25-26 June 2019. Biologicals 2020; 65:50-59. [PMID: 31959504 DOI: 10.1016/j.biologicals.2019.12.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 12/20/2019] [Indexed: 10/25/2022] Open
Abstract
The first global workshop on implementation of the WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products adopted by the WHO Expert Committee in 2018 was held in June 2019. The workshop participants recognized that the principles based on sound science and the potential for risk, as described in the WHO Guidelines on post-approval changes, which constitute the global standard for product life-cycle management are providing clarity and helping national regulatory authorities in establishing guidance while improving time-lines for an efficient regulation of products. Consequently, the regulatory situation for post-approval changes and guideline implementation is changing but there is a disparity between different countries. While the guidelines are gradually being implemented in some countries and also being considered in other countries, the need for regional workshops and further training on post-approval changes was a common theme reiterated by many participants. Given the complexities relating to post-approval changes in different regions/countries, there was a clear understanding among all participants that an efficient approach for product life-cycle management at a national level is needed to ensure faster availability of high standard, safe and efficacious medicines to patients as per the World Health Assembly Resolution 67.21.
Collapse
Affiliation(s)
- Meenu Wadhwa
- National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.
| | - Hye-Na Kang
- World Health Organization, Avenue Appia 20, CH-1211, Geneva, Switzerland.
| | - Teeranart Jivapaisarnpong
- National Biopharmaceutical Facility, King Mongkut's University of Technology Thonburi, Bangkhuntian, Bangkok, 10150, Thailand.
| | -
- International MSD International GmbH, Singapore
| | | | | | - Mary Casas Levano
- General Directorate of Medicines Supplies and Drugs (DIGEMID), San Miguel, Peru
| | | | | | | | | | | | | | - Kyung Min Choi
- Ministry of Food and Drug Safety (MFDS), Republic of Korea
| | | | | | | | - Mumun Gencoglu
- International Federation of Pharmaceutical Manufacturers Association, Switzerland
| | | | | | | | | | | | | | | | - Aleksei Iarutkin
- Federal Service for Surveillance in Healthcare (Roszdravnadzor), Russian Federation
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Desi Eka Putri
- National Agency of Drug and Food Control (NADFC), Indonesia
| | | | | | - Maria Savkina
- The FSBI "SCEEMP of the Ministry of Health of the Russian Federation, Russian Federation
| | | | | | | | | | | | | | - HyeonHo Song
- ILDONG Pharmaceutical Co., Ltd, Republic of Korea
| | | | | | - Meenu Wadhwa
- National Institute for Biological Standards and Control, United Kingdom
| | | | | | | |
Collapse
|